G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells.
Antiestrogen
Breast cancer
Epithelial mesenchymal transition
Estrogen receptor
G0S2
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
22
12
2022
revised:
12
04
2023
accepted:
14
04
2023
medline:
23
4
2023
pubmed:
23
4
2023
entrez:
22
04
2023
Statut:
ppublish
Résumé
G0/G1 switch gene 2 (G0S2) is known to inhibit lipolysis by inhibiting adipose triglyceride lipase (ATGL). In this report, we dissect the role of G0S2 in ER+ versus ER- breast cancer. Overexpression of G0S2 in ER- cells increased cell proliferation, while G0S2 overexpression in ER+ cells decreased cell proliferation. Transcriptome analysis revealed that G0S2 mediated distinct but overlapping transcriptional responses in ER- and ER+ cells. G0S2 reduced genes associated with an epithelial phenotype, especially in ER- cells, including CDH1, ELF3, STEAP4 and TACSTD2, suggesting promotion of the epithelial-mesenchymal transition (EMT). G0S2 also repressed estrogen signaling and estrogen receptor target gene signatures, especially in ER+ cells, including TFF1 and TFF3. In addition, G0S2 overexpression increased cell migration in ER- cells and increased estrogen deprivation sensitivity in ER+ cells. Interestingly, two genes downstream of ATGL in fat utilization and very important in steroid hormone biosynthesis, HMGCS1 and HMGCS2, were downregulated in G0S2 overexpressing ER+ cells. In addition, HSD17B11, a gene that converts estradiol to its less estrogenic derivative, estrone, was highly upregulated in G0S2 overexpressing ER+ cells, suggesting G0S2 overexpression has a negative effect on estradiol production and maintenance. High expression of G0S2 and HSD17B11 was associated with improved relapse-free survival in breast cancer patients while high expression of HMGSC1 was associated with poor survival. Finally, we deleted G0S2 in breast cancer-prone MMTV-PyMT mice. Our data indicates a complex role for G0S2 in breast cancer, dependent on ER status, that may be partially mediated by suppression of the estrogen signaling pathway.
Identifiants
pubmed: 37086619
pii: S1936-5233(23)00062-1
doi: 10.1016/j.tranon.2023.101676
pmc: PMC10214302
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101676Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Int J Oncol. 2008 Aug;33(2):397-404
pubmed: 18636162
Int J Cancer. 2010 Apr 15;126(8):1895-1902
pubmed: 19816938
Biochem Biophys Res Commun. 2009 Dec 25;390(4):1283-7
pubmed: 19878646
Oncotarget. 2015 Sep 29;6(29):28282-95
pubmed: 26318046
J Cancer Res Clin Oncol. 2018 Jul;144(7):1347-1355
pubmed: 29675790
Bioinformation. 2019 Dec 9;15(11):799-805
pubmed: 31902979
Nature. 1990 Feb 1;343(6257):425-30
pubmed: 1967820
Explor Target Antitumor Ther. 2022;3(4):480-496
pubmed: 36071983
Endocr Rev. 2004 Dec;25(6):947-70
pubmed: 15583024
Cancer Res. 2004 Sep 1;64(17):5973-81
pubmed: 15342376
Cancer Res. 2016 Mar 1;76(5):1204-13
pubmed: 26837760
Nat Commun. 2017 Oct 11;8(1):864
pubmed: 29021522
Leuk Res. 2016 Jan;40:100-2
pubmed: 26654706
Cancer Res. 2009 Sep 1;69(17):6782-9
pubmed: 19706769
J Clin Endocrinol Metab. 2013 Jan;98(1):E174-84
pubmed: 23093492
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
J Exp Clin Cancer Res. 2019 Apr 5;38(1):147
pubmed: 30953555
PLoS One. 2021 Jul 14;16(7):e0249164
pubmed: 34260600
PLoS One. 2016 Jun 01;11(6):e0156742
pubmed: 27248498
Clin Cancer Res. 2019 Jun 1;25(11):3276-3288
pubmed: 30770352
J Lipid Res. 2012 Nov;53(11):2307-17
pubmed: 22891293
Endocrinology. 2003 May;144(5):2084-91
pubmed: 12697717
Mol Cell Endocrinol. 2001 Jan 22;171(1-2):111-7
pubmed: 11165019
J Leukoc Biol. 2017 Mar;101(3):655-664
pubmed: 27605212
Mol Oncol. 2022 Feb;16(3):683-698
pubmed: 34482638
EBioMedicine. 2016 Nov;13:262-273
pubmed: 27745900
Trends Pharmacol Sci. 2008 Oct;29(10):510-4
pubmed: 18722677
Cancers (Basel). 2022 Nov 05;14(21):
pubmed: 36358862
Biochim Biophys Acta. 2013 Feb;1831(2):276-81
pubmed: 23032787
Leuk Res. 2014 Feb;38(2):210-7
pubmed: 24183236
Cancer Lett. 2020 Nov 28;493:266-283
pubmed: 32861706
Cell Metab. 2010 Mar 3;11(3):194-205
pubmed: 20197052
CA Cancer J Clin. 2022 Nov;72(6):524-541
pubmed: 36190501
Science. 2013 Nov 29;342(6162):1094-8
pubmed: 24288332
PLoS Genet. 2017 May 1;13(5):e1006716
pubmed: 28459858
Cell Cycle. 2017;16(21):2146-2155
pubmed: 28910567
J Clin Endocrinol Metab. 2022 Sep 28;107(10):2892-2899
pubmed: 35929659
Mol Cell Biochem. 2016 Jan;411(1-2):35-42
pubmed: 26472732
Front Oncol. 2022 Jul 13;12:944025
pubmed: 35912266
Cell Death Differ. 2014 Jul;21(7):1071-80
pubmed: 24583640
Genes (Basel). 2021 Sep 17;12(9):
pubmed: 34573418
Oncotarget. 2015 Oct 20;6(32):33253-68
pubmed: 26427334
Biomol Ther (Seoul). 2019 Jul 5;27(6):591-602
pubmed: 31272137
Cancer Biol Ther. 2014 May;15(5):643-50
pubmed: 24556704
Biochem Pharmacol. 2006 May 14;71(10):1459-69
pubmed: 16554039
Mediators Inflamm. 2020 Sep 30;2020:4286047
pubmed: 33061827
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Oct;1862(10 Pt B):1146-1154
pubmed: 28645852
DNA Cell Biol. 1991 Oct;10(8):581-91
pubmed: 1930693
Tissue Barriers. 2022 Oct 2;10(4):2005420
pubmed: 34821540
PLoS One. 2017 Oct 26;12(10):e0187047
pubmed: 29073263
PLoS One. 2018 Nov 2;13(11):e0206552
pubmed: 30388142
J Clin Med. 2022 Oct 05;11(19):
pubmed: 36233758